- Cellipont Bioservices has partnered with Ernexa Therapeutics to advance the development and clinical manufacturing of the ovarian cancer cell therapy ERNA-101.
- The collaboration will focus on Engineering, Differentiation, and Production (EDP) activities to enable cGMP manufacturing and clinical trials.
Cellipont Bioservices, a cell therapy Contract Development and Manufacturing Organisation (CDMO), has announced a collaboration with Ernexa Therapeutics (Nasdaq: ERNA) to support the development and manufacturing of ERNA-101, Ernexa’s lead cell therapy candidate for the treatment of ovarian cancer.
The partnership will centre on Engineering, Differentiation, and Production (EDP) activities to progress ERNA-101 into clinical manufacturing and trials. The therapy is based on Ernexa’s induced mesenchymal stem cell (iMSC) platform, designed to create scalable, off-the-shelf treatments for patients with advanced cancer and autoimmune diseases.
“We are pleased to collaborate with Ernexa Therapeutics as they advance a bold and highly differentiated approach to treating cancer. Supporting the development of synthetic, allogeneic iMSC therapies like ERNA-101 aligns with our commitment to enabling scientific innovation through collaborative, high-quality cell therapy manufacturing.”
Darren Head, CEO of Cellipont Bioservices
Ernexa’s iMSC platform is derived from engineered induced pluripotent stem cells (iPSCs) and aims to enhance immune system activation against tumours. Preclinical studies presented at the AACR and ASCO annual meetings showed that ERNA-101 has the potential to convert immunologically “cold” tumours into “hot” ones, promoting immune infiltration and tumour suppression.
Through the collaboration, Cellipont will support current Good Manufacturing Practice (cGMP) development and scale-up of ERNA-101’s production process, paving the way for its entry into clinical testing.
